NFLX breaking out at $60 feels like a legit momentum trade. I’m leaning long with tight stops, then scaling out into $65-$70. If it stalls, I’ll fade the pop and rotate into MSFT or TSLA instead.
I’ve held NFLX since $45 and added today. Feels exciting, but I’m nervous about ad spend and competition. Holding for now.
Rates still sticky; streaming multiples feel stretched.
Market loves a headline beat, but we keep ignoring the revenue miss and thin guidance. Why should MRNA's stock move more than the S&P? Feels like chasing hype over substance again.
Earnings beat, but is this sustainable?
Seen this movie before: strong quarter, shaky outlook. In past cycles, the real winners were cash-flowing names like JPM and MSFT, not the biotech headlines.
